Pregnancy outcomes in women exposed to efavirenz and nevirapine: An appraisal of the IeDEA West Africa and ANRS databases, abidjan, Côte d'Ivoire

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue 2, 2011, Pages 183-187

  Ekouevi, Didier K ^a,b,c   Coffie, Patrick A ^a,b,c   Ouattara, Eric ^a,b,c   Moh, Raoul ^a,b,c   Amani Bosse, Clarisse ^d   Messou, Eugene ^a,e   Sissoko, Marcel ^f   Anglaret, Xavier ^a,b,c   Eholié, Serge P ^a,g   Danel, Christine ^a,b,c   Dabis, François ^b,c  

^a Programme PAC CI   (Côte d’Ivoire)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c INSERM   (France)

^d ACONDA   (Côte d’Ivoire)

^e CePReF   (Côte d’Ivoire)

^f Centre Intégré de Recherche Biomédicale Abidjan CIRBA   (Côte d’Ivoire)

^g CENTRE HOSPITALIER UNIVERSITAIRE DE TREICHVILLE   (Côte d’Ivoire)

Author keywords

Africa; congenital abnormalities; efavirenz; HIV infection; pregnancy outcomes

Indexed keywords

CD4 ANTIGEN; EFAVIRENZ; NEVIRAPINE;

ADULT; AMENORRHEA; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPONTANEOUS ABORTION; STILLBIRTH;

EID: 78751607758     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181ff04e6     Document Type: Article

References (21)

1. World Health Organization.Rapid advice: use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. November 2009. Available at: http://www.who.int/hiv/pub/mtct/rapid-advice-mtct.pdf. Accessed 27 April 2010
2. De Santis M, Carducci B, De Santis L, et al. Periconceptional exposure to efavirenz and neural tube defects. Arch Intern Med. 2002;162:355.
3. Fundaro C, Genovese O, Rendeli C, et al. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS. 2002;16:299-300.
4. Saitoh A, Hull AD, Franklin P, et al. Myelomeningocele in an infant with intrauterine exposure to efavirenz. J Perinatol. 2005;25:555-556.
5. Bashi J, Balestre E, Messou E, et al. Time trends in demographic and clinical characteristics of adult patients on HAART initiation in West Africa]. Med Mal Infect. 2010;40:449-455. [article in French].
6. Calmy A, Pinoges L, Szumilin E, et al. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS. 2006;20:1163-1169.
7. Toure S, Kouadio B, Seyler C, et al. Rapid scaling-up of antiretroviral therapy in 10,000 adults in Cote d'Ivoire: 2-year outcomes and determinants. AIDS. 2008;22:873-882.
8. Myer L, Carter RJ, Katyal M, et al. Impact of antiretroviral therapy on incidence of pregnancy among HIV-infected women in Sub-Saharan Africa: a cohort study. PLoS Med. 2010;7:e1000229.
9. Viho I, Becquet R, Ekouevi DK, et al. Alternatives to prolonged breastfeeding and incidence of pregnancies among HIV-infected women: The ANRS 1201-1202 Ditrame Plus Cohort in Abidjan, Côte d'Ivoire, 2001 to 2005. Presented at: 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA. Abstract 73.
10. Bussmann H, Wester CW, Wester CN, et al. Pregnancy rates and birth outcomes among women on efavirenz-containing highly active anti-retroviral therapy in Botswana. J Acquir Immune Defic Syndr. 2007;45: 269-273.
11. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 Through 31 July 2009. Wilmington, NC: Registry Coordinating Center; 2009. Available at www.APRegistry.com. Accessed April 27, 2010.
12. Bera E, McCausland K, Nonkwelo R, et al. Birth defects following exposure to efavirenz-based antiretroviral therapy during pregnancy: a study at a regional South African hospital. AIDS. 2010;24:283-289.
13. Townsend CL, Willey BA, Cortina-Borja M, et al. Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990-2007. AIDS. 2009;23:519-524.
14. Floridia M, Tamburrini E, Bucceri A, et al. Pregnancy outcomes and antiretroviral treatment in a national cohort of pregnant women with HIV: overall rates and differences according to nationality. BJOG. 2007;114: 896-900.
15. Jeantils V, Khuong MA, Delassus JL, et al. Efavirenz (Sustiva) in pregnancy: a study about 12 HIV patients. Gynecol Obstet Fertil. 2006; 34:593-596. [article in French].
16. Danel C, Moh R, Anzian A, et al. Tolerance and acceptability of an efavirenz-based regimen in 740 adults (predominantly women) in West Africa. J Acquir Immune Defic Syndr. 2006;42:29-35.
17. Rossouw T. Quantifying antiretroviral risk in pregnancy. S Afr Med J. 2007;97:1014-1016.
18. Laher F, Forrest J, Mohapi L, et al. Efavirenz conceptions in Soweto, South Africa. Presented at: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 19-22, 2009; Cape Town, South Africa. Abstract TUPEC047.
19. Patel D, Thorne C, Fiore S, et al. Does highly active antiretroviral therapy increase the risk of congenital abnormalities in HIV-infected women? J Acquir Immune Defic Syndr. 2005;40:116-118.
20. Ford N, Mofenson L, Kranzer K, et al. Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. AIDS. 2010;24:1451-1470.
21. World Health Organization. Rapid advice. Use of antiretroviral drug for treating pregnant women and preventing HIV infection in infants. November 2009. Available at: http://www.who.int/hiv/pub/mtct/rapid-advice-mtct.pdf. Accessed May 30, 2010.